Xultophy is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.
Novo Nordisk announced Switzerland as the first country to launch Xultophy (IDegLira) for people with Type 2 Diabetes. Xultophy is...
Novo Nordisk announced that the FDA has approved the New Drug Application (NDA) for Xultophy 100/3.6.(iDegLira in the EU). Xultophy...
Novo Nordisk announced new phase IIIb trial (DUAL VII) results with Xultophy (IDegLira). Xultophy is a once-daily, single injection fixed...
EXTRA study data on Xultophy in type 2 diabetes published in Diabetes, Obesity and Metabolism
Novo Nordisk announced that the European Commission has granted marketing authorisation for Xultophy for the treatment of Type 2 Diabetes...
According to a new post-hoc analysis, in people with type 2 diabetes, Xultophy (insulin degludec/liraglutide), from Novo Nordisk, significantly reduced...
Xultophy (insulin degludec and liraglutide injection) provided superior blood sugar reduction (HbA1c) compared to insulin glargine U-100 (1.94% vs 1.68%...
New phase IIIb findings showed adults with type 2 diabetes treated with Xultophy (IDegLira- insulin degludec + liraglutide), a once-daily,...